Evelo Biosciences, Inc.: Evelo Biosciences Reports First Quarter 2021 Financial Results and Business Highlights
-Presented further positive data from Phase 1b clinical trial of EDP1815 at International Society of Atopic Dermatitis Meeting-
-Strengthened leadership team with appointments of Luca Scavo as Chief Financial Officer and Julie H. McHugh to Board of Directors-
-Announced strategic collaboration with Abdul Latif Jameel Health to develop and commercialize EDP1815 in select developing markets-
-Multiple clinical data readouts expected over next 18 months-
-Management to host conference call at 8:30 a.m. ET-
CAMBRIDGE, Mass., April 29, 2021 (GLOBE NEWSWIRE) Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines, today reported financial results and business highlights for the first quarter 2021.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Evelo Biosciences Reports First Quarter 2021 Financial Results and Business Highlights
Evelo Biosciences, Inc.April 29, 2021 GMT
–Presented further positive data from Phase 1b clinical trial of EDP1815 at International Society of Atopic Dermatitis Meeting– –Strengthened leadership team with appointments of Luca Scavo as Chief Financial Officer and Julie H. McHugh to Board of Directors– –Announced strategic collaboration with Abdul Latif Jameel Health to develop and commercialize EDP1815 in select developing markets– –Multiple clinical data readouts expected over next 18 months– –Management to host conference call at 8:30 a.m. ET–
email article
A topical pan-Janus kinase (JAK) inhibitor significantly improved atopic dermatitis (AD) after 8 weeks in a randomized, multidose, vehicle-controlled trial.
Two-thirds of patients treated with the highest dose of delgocitinib cream had at least 75% improvement in the Eczema Area and Severity Index (EASI 75). From 40% to 56% of patients randomized to lower doses of delgocitinib also had EASI 75 responses at 8 weeks. In contrast, 20.8% of patients allocated to a control cream had EASI 75 responses.
Investigator Global Assessment-Atopic Dermatitis (IGA-AD), dermatology-specific quality of life (QoL), itch and other key outcomes also improved significantly as compared with the control group, reported Jonathan Silverberg, MD, of George Washington University in Washington, at the American Academy of Dermatology virtual meeting.
LEO Pharma
LEO Pharma Presents Long-Term Safety and Efficacy Data for Tralokinumab in Adults With Moderate-to-Severe Atopic Dermatitis at AAD VMX 2021
Monday, April 26, 2021 1:00PM IST (7:30AM GMT)
Ballerup, Denmark & Madison, N.J., United States:
Interim analysis at 56 weeks from ECZTEND, an open-label extension trial, demonstrates sustainable and durable efficacy of tralokinumab in adult patients
1
Patients enrolled in ECZTRA 1 and 2 parent trials who continued into ECZTEND have now been treated with tralokinumab for two years
1
1
LEO Pharma A/S, a global leader in medical dermatology, today announced results on the long-term safety and efficacy profile of tralokinumab in adult patients with moderate-to-severe atopic dermatitis. Results were shared as an oral presentation during the American Academy of Dermatology Virtual Meeting Experience (AAD VMX) 2021.
BMS deucravacitinib tops Otezla in two psoriasis studies pharmatimes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmatimes.com Daily Mail and Mail on Sunday newspapers.